Analyst Concall
Alkem Lab aims at INR-10-bln sales from medi-tech segment
This story was originally published at 19:07 IST on 13 February 2026
Register to read our real-time news.Informist, Friday, Feb. 13, 2026
Please click here to read all liners published on this story
--Alkem Lab: To focus on orthopaedic, cardio pdts under medical devices ops
--CONTEXT: Comments by Alkem Lab's mgmt in post-earnings analyst concall
--Alkem Lab: Targeting sales of INR 10 bln under medi-tech segment in 3-5 yrs
--Alkem Lab: Target 20-22% EBITDA margin under medi-tech segment in 3-5 yrs
--CONTEXT: Alkem Lab has bought 55% stake in Occlutech Holding
--Alkem Lab: Occlutech is R&D centric company, product portfolio is strong
--Alkem Lab: May acquire remaining promoter stake in Occlutech in a few yrs
--Alkem Lab: Initial investment in Occlutech INR 11 bln
--Alkem Lab:May invest INR 1 bln-INR 2 bln more on Occlutech R&D going ahead
--Alkem Lab: Occlutech a platform to gain entry into new markets
By Narayana Krishna and Shruti Nair
MUMBAI – Alkem Laboratories Ltd. is targeting INR 10 billion revenue from its medical technology devices business in the next 2-3 years with a focus on cardiology and orthopaedic segment products, the company management said in a post-earnings investor call.
Alkem Lab Friday announced its plans to acquire a 55% stake in a Switzerland-headquartered firm Occlutech Holding AG, which makes advanced cardiovascular devices. The company said its initial investment for the acquisition will be at INR 11 billion and it may invest INR 1 billion to INR 2 billion, mainly on research and development. Alkem Lab acquired Occlutech's stake through its medi-tech business arm Alkem MedTech Pvt. Ltd.
The acquisition is aimed to be used as a platform to gain entry into new markets, Alkem Lab said. The company said it may also buy the remaining stake from the promoters in the future. Though Alkem Lab will own a majority stake, the current management at Occlutech will lead the operations in the immediate future.
Reiterating its target to achieve a double-digit revenue growth for 2025-26 (Apr-Mar), the company said the medi-tech business will significantly contribute to its profitability going forward.
For the December quarter, Alkem Lab reported consolidated net profit of INR 6.36 billion, up 1.6% on year. The growth was slowest in the last 11 quarters. The company's revenue for the quarter rose nearly 11% on year to 37.37 billion. More
Alkem Lab is expecting the acquired entity to contribute around INR 6 billion in 2026 and around INR 7.8 billion in 2027. The company is expecting Occlutech revenue to grow at a compounded annual growth rate of 14% in the next five years through its existing products. The medi-tech segment is expected to achieve earnings before interest, tax, depreciation, and amortisation margin of 20-22% in next 3-5 years. Alkem Lab said Occlutech is a research and development centric company with a lot of products in the pipeline and expects the company to provide growth opportunities across new markets.
On Friday, shares of Alkem Laboratories closed 8% lower at INR 5,402.50 on the National Stock Exchange. End
IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
